Larimar Therapeutics, Inc. financial data

Symbol
LRMR on Nasdaq
Location
Three Bala Plaza East. Suite 506, Bala Cynwyd, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 805 % -38.1%
Debt-to-equity 16.6 % +48.9%
Return On Equity -62.9 % -66.3%
Return On Assets -54 % -58.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85.6M shares +34.1%
Common Stock, Shares, Outstanding 64M shares +0.35%
Entity Public Float 314M USD
Common Stock, Value, Issued 64K USD 0%
Weighted Average Number of Shares Outstanding, Basic 64M shares +0.35%
Weighted Average Number of Shares Outstanding, Diluted 64M shares +0.35%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 90.6M USD +81.7%
General and Administrative Expense 18M USD +12.4%
Operating Income (Loss) -109M USD -64.9%
Nonoperating Income (Expense) 8.75M USD +16.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -99.8M USD -71%
Earnings Per Share, Basic -1 USD/shares -42.3%
Earnings Per Share, Diluted -1 USD/shares -42.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.6M USD -36.3%
Cash, Cash Equivalents, and Short-term Investments 139M USD -38.7%
Assets, Current 146M USD -37%
Property, Plant and Equipment, Net 797K USD -5.57%
Operating Lease, Right-of-Use Asset 2.47M USD -23.2%
Other Assets, Noncurrent 561K USD -11.8%
Assets 150M USD -36.8%
Accounts Payable, Current 4.17M USD +42.9%
Employee-related Liabilities, Current 2.15M USD +39.9%
Accrued Liabilities, Current 21.4M USD +23.8%
Liabilities, Current 26.6M USD +26%
Operating Lease, Liability, Noncurrent 3.49M USD -24.3%
Liabilities 30.1M USD +17%
Accumulated Other Comprehensive Income (Loss), Net of Tax -9K USD +94%
Retained Earnings (Accumulated Deficit) -325M USD -44.4%
Stockholders' Equity Attributable to Parent 120M USD -43.3%
Liabilities and Equity 150M USD -36.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26.5M USD -155%
Net Cash Provided by (Used in) Financing Activities 162M USD
Net Cash Provided by (Used in) Investing Activities 14.4M USD
Common Stock, Shares Authorized 115M shares 0%
Common Stock, Shares, Issued 64M shares +0.35%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1M USD -115%
Deferred Tax Assets, Valuation Allowance 173M USD +22%
Deferred Tax Assets, Gross 174M USD +21.9%
Operating Lease, Liability 4.61M USD -17.5%
Depreciation 88K USD +10%
Payments to Acquire Property, Plant, and Equipment 49K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -99.6M USD -70.3%
Lessee, Operating Lease, Liability, to be Paid 5.68M USD -21.1%
Property, Plant and Equipment, Gross 2.52M USD +12.5%
Operating Lease, Liability, Current 1.13M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.27M USD -13.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.48M USD -4.21%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.06M USD -33.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.19M USD -6.24%
Deferred Tax Assets, Operating Loss Carryforwards 50.2M USD +11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 959K USD -19.3%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 8.03M USD -1.71%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%